bdm deal with cdc on h5n1 bird flu, page-25

re: basic pharmacokinetics sorry tjw, the pharmacokinetic of relenza are quite clear,

http://www.rxlist.com/cgi/generic2/zanam_cp.htm

nothing locks up the neuraminidase "permanently" there is always association/disassociation and excretion

otherwise there would be no need for twice daily dosing for a week

dimeric zanamivir has extended residence time in the lung due to increased molecular weight and a "capacity factor K"

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15828835&query_hl=1&itool=pubmed_DocSum

and by cross linking neuraminidase has a much incresased potency.

Peramivir was produced using the same "lock and key" principles as zanamivir, they have slightly different resistance profiles and peramivir seems slightly more potent

http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=11181354

but the difference is minor.